175 related articles for article (PubMed ID: 12372830)
1. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif.
Colombo G; Curnis F; De Mori GM; Gasparri A; Longoni C; Sacchi A; Longhi R; Corti A
J Biol Chem; 2002 Dec; 277(49):47891-7. PubMed ID: 12372830
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif.
Di Matteo P; Curnis F; Longhi R; Colombo G; Sacchi A; Crippa L; Protti MP; Ponzoni M; Toma S; Corti A
Mol Immunol; 2006 Apr; 43(10):1509-18. PubMed ID: 16337683
[TBL] [Abstract][Full Text] [Related]
3. NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity.
Corti A; Gasparri AM; Sacchi A; Colombo B; Monieri M; Rrapaj E; Ferreri AJM; Curnis F
Mol Pharm; 2020 Oct; 17(10):3813-3824. PubMed ID: 32805112
[TBL] [Abstract][Full Text] [Related]
4. Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching.
Curnis F; Cattaneo A; Longhi R; Sacchi A; Gasparri AM; Pastorino F; Di Matteo P; Traversari C; Bachi A; Ponzoni M; Rizzardi GP; Corti A
J Biol Chem; 2010 Mar; 285(12):9114-23. PubMed ID: 20064928
[TBL] [Abstract][Full Text] [Related]
5. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
[TBL] [Abstract][Full Text] [Related]
6. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
Corti A; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():104-12. PubMed ID: 15650236
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
Curnis F; Sacchi A; Borgna L; Magni F; Gasparri A; Corti A
Nat Biotechnol; 2000 Nov; 18(11):1185-90. PubMed ID: 11062439
[TBL] [Abstract][Full Text] [Related]
8. Solution state conformation and degradation of cyclopeptides containing an NGR motif.
Füzéry AK; Mihala N; Szabó P; Perczel A; Giavazzi R; Süli-Vargha H
J Pept Sci; 2005 Jan; 11(1):53-9. PubMed ID: 15635727
[TBL] [Abstract][Full Text] [Related]
9. Structure and activity of CPNGRC: a modified CD13/APN peptidic homing motif.
Plesniak LA; Salzameda B; Hinderberger H; Regan E; Kahn J; Mills SA; Teriete P; Yao Y; Jennings P; Marassi F; Adams JA
Chem Biol Drug Des; 2010 Jun; 75(6):551-62. PubMed ID: 20374250
[TBL] [Abstract][Full Text] [Related]
10. Disulfide bond formation in NGR fiber-modified adenovirus is essential for retargeting to aminopeptidase N.
Majhen D; Gabrilovac J; Eloit M; Richardson J; Ambriović-Ristov A
Biochem Biophys Res Commun; 2006 Sep; 348(1):278-87. PubMed ID: 16876116
[TBL] [Abstract][Full Text] [Related]
11. The asparagine-stabilized beta-turn of apamin: contribution to structural stability from dynamics simulation and amide hydrogen exchange analysis.
Dempsey CE; Sessions RB; Lamble NV; Campbell SJ
Biochemistry; 2000 Dec; 39(51):15944-52. PubMed ID: 11123921
[TBL] [Abstract][Full Text] [Related]
12. Glycine
Corti A; Gasparri AM; Ghitti M; Sacchi A; Sudati F; Fiocchi M; Buttiglione V; Perani L; Gori A; Valtorta S; Moresco RM; Pastorino F; Ponzoni M; Musco G; Curnis F
Adv Funct Mater; 2017 Sep; 27(36):. PubMed ID: 28979182
[TBL] [Abstract][Full Text] [Related]
13. On the intrinsic propensity of the Asn-Gly sequence to fold into type I' β-turn: molecular dynamics simulations of Asn-Gly β-turn containing peptide sequences.
Sharadadevi A; Nagaraj R
J Biomol Struct Dyn; 2018 Nov; 36(15):3916-3925. PubMed ID: 29137532
[No Abstract] [Full Text] [Related]
14. The neovasculature homing motif NGR: more than meets the eye.
Corti A; Curnis F; Arap W; Pasqualini R
Blood; 2008 Oct; 112(7):2628-35. PubMed ID: 18574027
[TBL] [Abstract][Full Text] [Related]
15. β-Amino acids containing peptides and click-cyclized peptide as β-turn mimics: a comparative study with 'conventional' lactam- and disulfide-bridged hexapeptides.
Larregola M; Lequin O; Karoyan P; Guianvarc'h D; Lavielle S
J Pept Sci; 2011 Sep; 17(9):632-43. PubMed ID: 21644250
[TBL] [Abstract][Full Text] [Related]
16. Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.
Jiang W; Jin G; Ma D; Wang F; Fu T; Chen X; Chen X; Jia K; Marikar FM; Hua Z
PLoS One; 2012; 7(5):e37132. PubMed ID: 22590653
[TBL] [Abstract][Full Text] [Related]
17. NGR-peptide-drug conjugates with dual targeting properties.
Enyedi KN; Tóth S; Szakács G; Mező G
PLoS One; 2017; 12(6):e0178632. PubMed ID: 28575020
[TBL] [Abstract][Full Text] [Related]
18. Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.
Li JJ; Chang SF; Liau II; Chan PC; Liu RS; Yen SH; Wang HE; Chang CA
J Biomed Sci; 2016 Jan; 23():15. PubMed ID: 26801910
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome.
Negussie AH; Miller JL; Reddy G; Drake SK; Wood BJ; Dreher MR
J Control Release; 2010 Apr; 143(2):265-73. PubMed ID: 20067811
[TBL] [Abstract][Full Text] [Related]
20.
Al-Mansoori L; Bashraheel SS; Qahtani ADA; O'Connor CD; Elsinga P; Goda SK
Oncotarget; 2020 Feb; 11(6):619-633. PubMed ID: 32110281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
